176 related articles for article (PubMed ID: 30217228)
21. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial.
Collet JP; Silvain J; Barthélémy O; Rangé G; Cayla G; Van Belle E; Cuisset T; Elhadad S; Schiele F; Lhoest N; Ohlmann P; Carrié D; Rousseau H; Aubry P; Monségu J; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Beygui F; Vicaut E; Montalescot G;
Lancet; 2014 Nov; 384(9954):1577-85. PubMed ID: 25037988
[TBL] [Abstract][Full Text] [Related]
22. Absorption kinetics of low-dose chewable aspirin--implications for acute coronary syndromes.
Hobl EL; Schmid RW; Stimpfl T; Ebner J; Jilma B
Eur J Clin Invest; 2015 Jan; 45(1):13-7. PubMed ID: 25402445
[TBL] [Abstract][Full Text] [Related]
23. Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Franchi F; Faz GT; Rollini F; Park Y; Cho JR; Thano E; Hu J; Kureti M; Aggarwal N; Durairaj A; Been L; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2016 Jun; 9(11):1089-98. PubMed ID: 27013060
[TBL] [Abstract][Full Text] [Related]
24. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
Patrick J; Dillaha L; Armas D; Sessa WC
Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
[TBL] [Abstract][Full Text] [Related]
26. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
27. Study design of the influence of SErotonin inhibition on patients with RENAl impairment or diabetes undergoing drug-eluting stent implantation (SERENADE) study: A multicenter, open-label, prospective, randomized study.
Lee SA; Suh JW; Park JJ; Yoon CH; Cho YS; Youn TJ; Chae IH; Kim HS; Kim SH; Choi DJ
Contemp Clin Trials; 2015 Jul; 43():20-4. PubMed ID: 25891091
[TBL] [Abstract][Full Text] [Related]
28. Celecoxib interferes to a limited extent with aspirin-mediated inhibition of platelets aggregation.
Ruzov M; Rimon G; Pikovsky O; Stepensky D
Br J Clin Pharmacol; 2016 Feb; 81(2):316-26. PubMed ID: 26456703
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/pharmacodynamic assessment of a novel, pharmaceutical lipid-aspirin complex: results of a randomized, crossover, bioequivalence study.
Angiolillo DJ; Bhatt DL; Lanza F; Cryer B; Dong JF; Jeske W; Zimmerman RR; von Chong E; Prats J; Deliargyris EN; Marathi U
J Thromb Thrombolysis; 2019 Nov; 48(4):554-562. PubMed ID: 31420787
[TBL] [Abstract][Full Text] [Related]
30. 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease.
Henry P; Vermillet A; Boval B; Guyetand C; Petroni T; Dillinger JG; Sideris G; Bal dit Sollier C; Drouet L
Thromb Haemost; 2011 Feb; 105(2):336-44. PubMed ID: 21136023
[TBL] [Abstract][Full Text] [Related]
31. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
Trials; 2015 Apr; 16():198. PubMed ID: 25925591
[TBL] [Abstract][Full Text] [Related]
32. Comparison of antiplatelet effect and tolerability of clopidogrel resinate with clopidogrel bisulfate in patients with coronary heart disease (CHD) or CHD-equivalent risks: a phase IV, prospective, double-dummy, parallel-group, 4-week noninferiority trial.
Suh JW; Seung KB; Gwak CH; Kim KS; Hong SJ; Park TH; Kim SH; Choi YJ; Joo SJ; Tahk SJ; Kim HS
Clin Ther; 2011 Aug; 33(8):1057-68. PubMed ID: 21816478
[TBL] [Abstract][Full Text] [Related]
33. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
[TBL] [Abstract][Full Text] [Related]
34. Combination of Xuesaitong and Aspirin Based on the Antiplatelet Effect and Gastrointestinal Injury: Study Protocol for a Randomized Controlled Noninferiority Trial.
Zhu BC; Xue CM; Lang R; Weng WL; Wang XJ; Lei ZZ; Zhang SS; Yang WH; Zhang WT; Hua GD
Evid Based Complement Alternat Med; 2021; 2021():5552506. PubMed ID: 34335822
[TBL] [Abstract][Full Text] [Related]
35. Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status.
Capranzano P; Ferreiro JL; Ueno M; Capodanno D; Dharmashankar K; Darlington A; Desai B; Tello-Montoliu A; Rollini F; Angiolillo DJ
Catheter Cardiovasc Interv; 2013 Jan; 81(1):42-9. PubMed ID: 22431415
[TBL] [Abstract][Full Text] [Related]
36. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.
Ikeda Y; Shimada K; Teramoto T; Uchiyama S; Yamazaki T; Oikawa S; Sugawara M; Ando K; Murata M; Yokoyama K; Ishizuka N
JAMA; 2014 Dec; 312(23):2510-20. PubMed ID: 25401325
[TBL] [Abstract][Full Text] [Related]
37. Low-molecular-weight heparin during instability in coronary artery disease, Fragmin during Instability in Coronary Artery Disease (FRISC) study group.
Lancet; 1996 Mar; 347(9001):561-8. PubMed ID: 8596317
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacodynamic modelling of aspirin- and Ibuprofen-induced inhibition of platelet aggregation in healthy subjects.
Hong Y; Gengo FM; Rainka MM; Bates VE; Mager DE
Clin Pharmacokinet; 2008; 47(2):129-37. PubMed ID: 18193919
[TBL] [Abstract][Full Text] [Related]
39. Dipyrone (metamizole) markedly interferes with platelet inhibition by aspirin in patients with acute and chronic pain: A case-control study.
Schmitz A; Romann L; Kienbaum P; Pavlaković G; Werdehausen R; Hohlfeld T
Eur J Anaesthesiol; 2017 May; 34(5):288-296. PubMed ID: 28030443
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
